March 26, 2020

Pfizer Announces Temporary Payment Terms Adjustment for Prevnar 13®
(Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])
and Trumenba® (Meningococcal Group B Vaccine)
Effective March 26, 2020 – May 31, 2020

Dear Healthcare Provider,

As a global healthcare company, Pfizer remains committed to meeting the needs of patients and those who care for patients, and we realize the strains the COVID-19 pandemic has placed on healthcare providers and healthcare systems. I am writing to provide notification of a temporary payment terms extension for Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and Trumenba® (Meningococcal Group B Vaccine).

Effective March 26, 2020, all open invoices dated January 1, 2020 or later for Pfizer vaccines purchased through primevaccines.pfizer.com or through Pfizer Customer Service for physicians, clinics, and group practices will automatically have an additional 30 days added to their existing payment terms. No action is required on your part. No new invoices will be issued; therefore, we recommend you simply make note of the additional 30 days on your current invoice. Additionally, all NEW orders for these customers placed directly through Pfizer between today and May 31, 2020 will have extended payment terms of 105 days with the 2% prompt pay discount.

These temporary payment terms will apply to any new vaccine orders placed either online at primevaccines.pfizer.com or through Pfizer Customer Service at 1-800-666-7248 through May 31, 2020.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Previous Payment Terms</th>
<th>Temporary Payment Terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevnar 13®</td>
<td>2% 75 days, Net 76</td>
<td>2% 105 days, Net 106</td>
</tr>
<tr>
<td>Trumenba®</td>
<td>2% 75 days, Net 76</td>
<td>2% 105 days, Net 106</td>
</tr>
</tbody>
</table>

Pfizer is committed to doing all we can to respond to the COVID-19 pandemic. Our Five Point Plan to help battle COVID-19 focuses on sharing tools and insights, marshaling our people, applying our drug development expertise, offering our manufacturing capabilities, improving future rapid response – as always, with a focus on global public health and safety and delivering medicines and vaccines to those in need.

Our manufacturing sites around the world are currently operational, and all product continues to flow from plants to markets. Our manufacturing and supply chain professionals have been working non-stop to ensure that the global supply of Pfizer medicines continue to be available to patients. Currently, we do not anticipate any COVID-19 related shortages of product in the United States.

During these unprecedented times, we understand your needs may have evolved due to fewer patients visiting physician offices for routine well-visit appointments. Therefore, we are asking our customers to only order product quantities needed to support patient needs at this time.

We encourage you to contact your Pfizer Vaccines Territory Manager with any questions you may have. Alternatively, please feel free to contact Pfizer Customer Service at 1-800-666-7248 for additional assistance.

Sincerely,

David Hering
Regional President Vaccines North America
Pfizer Inc.